RE:RE:RE:RE:RE:Riovant in plans to sell UC drug to Roche for US$7 Billion
" The market for UC and Crohn’s, often grouped as inflammatory bowel disease (IBD), was valued at $17.3 Billion in 2021 by Transparency Market Research. The group projected this number would rise to more than $34 billion by 2031. Growth Plus Reports puts this market value at nearly $40 Billion. "
https://www.biospace.com/article/roche-in-talks-to-buy-stomach-drug-from-roivant-for-7b-report-/
In comparision, the global HER-2 negative breast cancer market alone, which is just one indication that ONCY is positioning pelareorp to address, was valued at USD $12.3 Billion in 2022 which expected to reach USD $27,4 Billion by 2030, at a CAGR 8.67%
from 2023-2030.
https://www.researchandmarkets.com/reports/5775762/global-her-2-negative-breast-cancer-market